コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 e (5.7% and 8.3%, respectively; 32% relative risk reduction).

2 ve effect on the risk of brain injuries (34% risk reduction).

3 confidence interval: -0.3% to 4.6%) absolute risk reduction.

4 s an indicator of treatment-related fracture risk reduction.

5 rd a new strategy for lipid-lowering and CVD risk reduction.

6 cified minimal clinically important relative risk reduction.

7 open a new avenue for cardiovascular disease risk reduction.

8 be aggressively targeted for cardiovascular risk reduction.

9 s of statin-dependent cardiovascular disease risk reduction.

10 tes medications did not confer a similar OAG risk reduction.

11 radiation provides an absolute locoregional risk reduction.

12 owing interest in nature-based solutions for risk reduction.

13 eta-blockers was associated with the largest risk reduction.

14 tiative study was used to calculate inferred risk reduction.

15 r a potential public health strategy for CVD risk reduction.

16 ntribution of ecosystem services to disaster risk reduction.

17 AP treatment may be beneficial for metabolic risk reduction.

18 ns aimed at breast density and breast cancer risk reduction.

19 ns have been associated with cardiometabolic risk reduction.

20 ussions of sexual development, behavior, and risk reduction.

21 prophylaxis and individualized counseling on risk reduction.

22 .3 (95% CI, .01-3.1), corresponding to a 70% risk reduction.

23 and event rates along with trial-based event risk reduction.

24 and hs-cTnI identify candidates for targeted risk reduction.

25 ve CAD, may represent a novel target for CVD risk reduction.

26 treatment, with or without a 20% behavioral risk reduction.

27 e sessions to train their network members in risk reduction.

28 les and checklists appears to yield stronger risk reductions.

29 cantly reduced that risk with large absolute risk reductions.

31 n in nonfatal MI benefit persisted (absolute risk reduction, 0.15 to 1.43 events per 1000 person-year

34 ients who did not undergo ablation (relative risk reduction: 0.08; 95% confidence interval: 0.02 to 0

35 ients who did not undergo ablation (relative risk reduction: 0.08; 95% confidence interval: 0.02 to 0

36 , which was lower than expected (ie, greater risk reduction); 1.01 (95% CI, 0.94-1.09) vs 0.90 (95% C

38 nt therapy (7 [5.8%] vs 19 [15.8%]; absolute risk reduction, 10%; 95% CI, 2.25%-17.75%; P = .01), and

40 ontrol (63 of 120 patients [52.5%]; absolute risk reduction, 15%; 95% CI, 2.56%-27.44%; P = .02).

41 cause (RR, 0.91; 95% CI, 0.85-0.97; absolute risk reduction, 2.6%; P=0.003).Cancer incidence was simi

44 n the control group (5.2% vs. 9.8%; relative risk reduction, 46.3% [95% confidence interval, 6.8 to 6

45 .31-87.25) of patients in the placebo group (risk reduction 5.05%; hazard ratio 0.95, 95% CI 0.80-1.1

46 ospitalizations was reduced by 59% (absolute risk reduction, 5.5%; 95% CI, 4.7%-6.1%) and readmission

47 ast 1 reoperation within 12 months (relative risk reduction, 59%; relative risk, 0.41 [95% CI, 0.23 t

48 mortality and all-cause mortality (relative risk reduction, 6.7% [95% CI, 1.2% to 13.6%]; absolute r

49 isk [RR], 0.84 [95% CI, 0.71-1.01]; absolute risk reduction, 6.8% [95% CI, -0.3% to 13.9%]; P = .07).

50 observed in humans and demonstrated the same risk reduction (70%) previously attained in women with h

51 om 19.9% to 11.5% (P < 0.001), with absolute risk reduction 8.4 (95% confidence interval, 6.3-10.5) f

53 hieved clinically significant cardiovascular risk reduction (a weight loss >/=5% or an increase of >5

54 t gradient (p=0.0277) of increasing relative risk reductions across the low (13%), intermediate (29%)

55 ality, reaching a plateau with more than 50% risk reduction after an administration-to-birth interval

57 ]), statin therapy led to a greater relative risk reduction among a subgroup at high genetic risk.

58 scribe approaches to optimize cardiovascular risk reduction among individuals reporting statin-associ

61 ular infections, physicians should regard on risk reduction and comply with etiologic approach of dia

65 associated with greater total cardiovascular risk reduction and specifically for myocardial infarctio

67 e (2.7% and 4.1%, respectively; 35% relative risk reduction), and death from any cause (5.7% and 8.3%

68 2), which was higher than expected (ie, less risk reduction); and 0.49 (95% CI, 0.34-0.71) vs 0.61 (9

70 illness have reported clinically significant risk reduction, and none have been replicated in communi

71 ions, although the magnitude of the ischemic risk reduction appeared to be enhanced with prasugrel.

73 se in the lowest subgroup had no significant risk reduction (ARR = 0.006, 95% CI: -0.007, 0.018; P =

74 isk [RR], 0.87; 95% CI, 0.78-0.96); absolute risk reduction (ARR) in events per 1000 patient-years (3

79 epeated self-harm (0.84, 0.77-0.91; absolute risk reduction [ARR] 2.6%, 1.5-3.7; numbers needed to tr

80 ent 1 CVD event/death over 5 years (absolute risk reduction [ARR] = 0.042, 95% CI: 0.018, 0.066; P =

81 [OR], 1.62 [95% CI, 1.31 to 2.00]; absolute risk reduction [ARR] in events per 100 infants, -12.0 [9

82 ically significant (12.9% vs 20.0%; absolute risk reduction [ARR] with infliximab, 7.1%; 95% confiden

83 (20.2%) died during their ICU stay (absolute risk reduction [ARR], 0.086 [95% CI, 0.017-0.150]; relat

84 are strategies by measuring effectiveness of risk reduction as a function of the features of projecte

85 ontrol, and likely to cardiovascular disease risk reduction, as statins have been over the past three

87 omorbidity burden (2 and >/=3), the absolute risk reduction associated with CRT-D over ICD alone appe

88 highest range of body mass index (BMI), the risk reduction associated with preoperative weight loss

89 P in predicting incident CKD and whether CKD risk reduction associates with progressive treatment-ind

91 cluding prevention products, procedures, and risk-reduction behaviours) into population-level effects

92 gher lipids were associated with greater CVD risk reduction benefits from intensive treatment, while

93 e 100 million or more people who may receive risk reduction benefits from reefs or bear hazard mitiga

94 l for atherosclerotic cardiovascular disease risk reduction benefits, adverse effects, drug-drug inte

95 There were no significant differences in risk reduction between the TAU and screening phases (23%

96 edicted benefit had significant absolute CVD risk reduction, but the overall ACCORD-BP participant sa

97 ed therapies contributes importantly to this risk reduction, but there is still room for improvement.

98 was the first large randomized trial of CVD risk reduction by community pharmacists, demonstrating a

101 t cause sudden infant death, the mainstay of risk reduction continues to be a safe sleep environment,

105 and STI knowledge, diagnosis, treatment, and risk reduction counselling can potentially reduce HIV an

107 timates of coronary heart disease and stroke risk reduction due to antihypertensive medication treatm

108 al, 0.31-0.72; P < 0.001) with a significant risk reduction during the second year of follow-up (haza

111 ce of hypertension accounted for the largest risk reduction, followed by a reduction in tobacco smoki

115 d plasma lutein/zeaxanthin score, we found a risk reduction for advanced AMD of about 40% in both wom

120 results were sensitive to alterations in the risk reduction for post-myocardial infarction events fro

121 Mendelian randomization analysis, the causal risk reduction for T2D was estimated to be 42% (causal O

122 e results in the experimental arm showed the risk reduction for the main end point to be < 9.64%.

125 risk, patients with PAD had larger absolute risk reductions for the primary end point (3.5% with PAD

126 ompleted statin trials show greater relative risk reductions for those patients at lower levels of ab

127 d targets was estimated by applying relative risk reductions from meta-analyses to the estimated risk

130 of 60 ml/min per 1.73 m(2) experienced a 12% risk reduction (hazard ratio [HR], 0.88; 95% confidence

131 h ADHD, medication was associated with a 58% risk reduction (hazard ratio, 0.42; 95% CI, 0.23-0.75),

132 th 14% among patients receiving placebo (81% risk reduction; hazard ratio in the enzalutamide group,

133 nd from other partners, the magnitude of the risk reduction he would gain with PrEP, and nonpharmacol

134 vs. 5.9% in the placebo group; 38% relative risk reduction), hospitalization for heart failure (2.7%

136 se of agranulocytosis, based on the possible risk reduction if all three SNPs are genotyped and carri

137 tion significantly reduced the 12-mo overall risk (reduction in overall risk: -19%; 95% CI, -7 to -41

140 n adjusted 32% (HR, 0.68; 95% CI, 0.47-0.98) risk reduction in all cancer-related deaths and a 68% re

141 .87, 0.79-0.96; p=0.007), and a 12% relative risk reduction in all-cause mortality (0.88, 0.81-0.95;

142 represented an intervention effect (absolute risk reduction in antibiotic prescribing) of -29% (95% C

143 tors; 20% of population) had a 3.2% absolute risk reduction in cardiovascular disease/MI/ischemic str

144 ted Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents of the Nation

145 ted Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents," several med

148 confidence interval: 2.9% to 9.7%) absolute risk reduction in CV death/MI/iCVA at 7 years with ezeti

149 py with defibrillator, with greater absolute risk reduction in death and HF among those with moderate

150 rehensive approach to cardiovascular disease risk reduction in HIV-infected patients with DM and meas

151 U setting, we found a 26% (SD, 23%) relative risk reduction in length of stay with these intervention

158 mple sizes needed to detect a 5-10% absolute risk reduction in outcomes within interventional trials

159 rathyroidectomy was associated with fracture risk reduction in patients regardless of whether they sa

161 ific, Marlborough, Massachusetts) for stroke risk reduction in patients with nonvalvular AF at multip

162 llator provided the greatest HF or mortality risk reduction in patients with SBP<110 mm Hg hazard rat

163 ransfusion was associated with 3.5% absolute risk reduction in postoperative myocardial infarction.

164 with edoxaban resulted in a greater absolute risk reduction in severe bleeding events and all-cause m

166 [CI], 0.85 to 1.20; P=0.90), for an absolute risk reduction in the EGDT group of -0.3 percentage poin

168 showed a clinically relevant and significant risk reduction in the pirfenidone group compared with th

170 treatment showed a significant 10% relative risk reduction in the three-point major adverse cardiova

172 OT, and JUPITER primary prevention, relative risk reduction in those at high genetic risk was 46% ver

174 analysis showed a significant cardiovascular risk reduction in those who used CPAP for >/=4 versus <4

175 of ACDs was associated with a 0.40% absolute risk reduction in vascular access site complications (95

176 y associated with incident AF with a greater risk reduction in women (hazard ratio per SD, 0.86; 95%

177 ervention to promote safe HIV disclosure and risk reduction in women seeking HIV counselling and test

178 relationship between the exercise volume and risk reductions in cardiovascular morbidity and mortalit

179 then investigated the relative and absolute risk reductions in coronary heart disease events with st

180 here was no clear evidence that proportional risk reductions in major cardiovascular disease differed

182 ent cancer in unsuspecting relatives through risk-reduction intervention in mutation carriers and to

184 idence is lacking about the effectiveness of risk reduction interventions in patients with asymptomat

185 independent of the agents used, significant risk reduction is found at all hypertension grades (stag

187 ich has the goals of fracture prevention and risk reduction, is moving beyond traditional monotherapi

188 iveness should be considered, additional CVD risk-reduction measures for adults with SBP/DBP <140/90

192 d by total estrogen levels, with the largest risk reductions occurring in women in the highest tertil

194 ute risk reduction of 0.15 (15%), a relative risk reduction of 0.75 (75%) and a number needed to trea

196 ing of SSBs with water was associated with a risk reduction of 10% (HR: 0.90; 95% CI: 0.85, 0.95).ASB

199 lyses on shunt dependency showed an absolute risk reduction of 24% for the intervention (LD, 2.2% [1

200 n vs 205 [19%] of 1055 for control, absolute risk reduction of 3.46%, 95% CI 0.21-6.73%, p=0.038) By

201 e, the high compliance group had an absolute risk reduction of 3.6% (P < 0.01), 2.9% (P < 0.01) and 1

203 AD, patients with PAD had a greater absolute risk reduction of 4.1% (number needed to treat: 25) due

204 7.8% (95% CI: 2.4, 12.3), corresponding to a risk reduction of 4.2% (95% CI: 0.3, 8.1) and a preventa

206 tatin therapy was associated with a relative risk reduction of 44% (95% confidence interval [CI], 22-

209 with water was associated with a significant risk reduction of 5% (HR: 0.95; 95% CI: 0.91, 0.99), whe

210 Based on previously reported data (relative risk reduction of 50%), the incremental gain in quality-

211 f protein associated with a maximum relative risk reduction of 62.4% (95% CI, 33.1 to 78.9; P<0.01).

212 k of recurrence and demonstrated an absolute risk reduction of 8.6% for stroke of any etiology (10.2%

216 ed trial that demonstrated an 11.7% absolute risk reduction of clinically significant POPF with use o

217 nary event, or nonfatal stroke, the relative risk reduction of combination therapy compared with mono

218 r there was a 7% absolute and a 24% relative risk reduction of death and dependency in the coiling gr

221 0.25-0.97) was associated with a significant risk reduction of HCC, while insulin (RR = 2.44, 95% CI

226 or morbidity outcome, whereas a significant risk reduction of severe neonatal brain injury was assoc

229 ll lead to greater understanding of specific risks, reduction of exposures, and improvement of health

230 it approach (ie, based on predicted absolute risk reduction over 10 years [ARR10] >/=2.3% from random

231 -2 risk indicators; 61%) had a 2.1% absolute risk reduction (P<0.001 each), translating to a number n

236 disciplinary cardiac rehabilitation (CR) and risk reduction program is an essential component of ASCV

237 effect of a rigorous cardiovascular disease risk reduction program on peripheral blood gene expressi

238 have examined the effect of a comprehensive risk-reduction program on long-term outcomes for patient

242 Meta-regression analyses showed relative risk reductions proportional to the magnitude of the blo

244 r-sexual provisioning, kin provisioning, and risk reduction reciprocity, three levels of cooperation

245 ] in group 2; P<0.001), showing 45% relative risk reduction (relative risk, 0.55; 95% confidence inte

246 ognosis (and driver an effective therapeutic risk reduction) remains one of the greatest ongoing deba

249 to guide patient education about lymphedema risk reduction strategies for those who undergo bilatera

250 t future episodes by developing personalized risk reduction strategies including, where possible, com

253 cation with sexual partners especially about risk reduction strategies, including preexposure prophyl

257 n elevated risk that would benefit most from risk-reduction strategies based on altering modifiable f

259 es were at higher risk of MACE, the absolute risk reduction tended to be greater in patients with ver

260 ector and adopting an ecological approach to risk reduction that addresses personal, societal, and cu

261 ndomized trials on relative and absolute CVD risk reduction that can occur when antihypertensive trea

262 or-positive first breast cancer, an absolute risk reduction that is consistent with findings from cli

264 th et al, "AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Ot

265 ical strategies that optimize cardiovascular risk reduction through LDL-C lowering need to be applied

266 RIM-3 trial, vemurafenib was associated with risk reduction versus dacarbazine of both death and prog

267 t 25, 2011, cladribine was associated with a risk reduction versus placebo for time to conversion to

268 acological therapy (n = 5,960), the absolute risk reduction was 1.9% with a 3-year number needed to t

270 <0.001), whereas in all others, the relative risk reduction was 24% (95% CI, 8-37; P=0.004) despite s

277 ion phase (HR, 0.55; 95% CI, 0.34-0.89), but risk reduction was not observed during the late postinte

282 eved from aerobic exercise, the magnitude of risk reduction was similar regardless of intensity of ae

288 nalyzed complications, whereas corresponding risk reductions were only occasionally encountered and l

290 pressures and heart failure hospitalization risk reduction with a novel implantable PA pressure moni

294 rapy underwent cataract extraction (adjusted risk reduction with intensive therapy, 48%; 95% CI, 23 t

299 l hemorrhage (ICH) and the benefit of stroke risk reduction with the use of oral anticoagulants for p

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。